Targeting immune checkpoints in hematological malignancies

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Immune checkpoint blockade (ICB) therapies like anti-PD-1 and anti-CTLA-4 have revolutionized solid tumor treatment.
• While immunotherapies improve hematological malignancy outcomes, ICB benefits are limited to specific immune-infiltrated tumors.
• Primary and acquired resistance to ICB in hematological malignancies necessitates understanding disease-specific immune microenvironments.

Purpose of the Study:

• To review recent advances in immune checkpoint blockade for hematological malignancies.
• To explore emerging roles of T-cell and innate immune checkpoint molecules as therapeutic targets.
• To discuss strategies for overcoming resistance and improving ICB efficacy.

Main Methods:

• Literature review of recent advances in ICB for hematological malignancies.
• Analysis of T-cell and innate immune checkpoint roles in hematological cancers.
• Discussion of therapeutic strategies targeting immune checkpoints.

Main Results:

• ICB efficacy in hematological malignancies is limited by resistance mechanisms.
• Novel T-cell checkpoints (beyond PD-1, CTLA-4) and innate checkpoints (on NK cells, macrophages) show therapeutic potential.
• Targeting innate checkpoints may enhance antibody-mediated cellular cytotoxicity and phagocytosis.

Conclusions:

• Understanding disease-specific immune microenvironments is essential for improving ICB efficacy in hematological malignancies.
• Targeting novel T-cell and innate immune checkpoints offers promising strategies to overcome resistance.
• ICB, particularly combined with innate immune checkpoint blockade, holds significant potential for treating hematological cancers.